Dr. Atul Deshpande is the CEO of IMMEDIATE Therapeutics, a clinical-stage biotech company advancing IMT-358, a first-in-class cardioprotective metabolic therapy for acute coronary syndromes and other ischemic emergencies. He brings over 20 years of leadership experience across biotech and pharma, spanning R&D, strategy, and commercialization. Prior to IMMTX, Atul was Chief Strategy Officer at Peptilogics, where he helped close a $75M+ raise for its peptide therapeutics platform in 2025. Previously, he served as Chief Strategy Officer and Head of U.S. Operations at Harbour BioMed, where he led global strategy and operations across the U.S. and EU, raising $400M+ and supported the company's Hong Kong Stock Exchange IPO. At Sanofi, Atul was Global Operations Head for the now $15B+ Dupixent franchise, responsible for launching the drug in over 50 markets. He also operation for the I&I franchise and led the R&D strategy for Sanofi’s Asia Pacific hub including market entry strategy across Asia. Earlier in his career, Atul spent several years as a management consultant supporting clients across the pharma value chain. He holds a Ph.D. in Neuroscience from UC Irvine, completed his postdoctoral fellowship at UCLA and an MBA from Cranfield University (UK).